INS and type 2 diabetes mellitus: The improvements in HOMA-B, HOMA-IR, and the proinsulin/insulin ratio observed in this review are clinically meaningful, as they suggest that semaglutide not only improves glycemic control but may also help slow the progressive decline of β-cell function that underlies type 2 diabetes.